Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Proof-of-Concept Randomized Controlled Trial (HCQ-CGN Trial)
Glomerular Diseases · 29.09.2026 · 6 (1) · 342-353
DOI: 10.1159/gdz/acyag005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Glomerular Diseases, online erschienen am 29.09.2026. Verfasst von Thitirat Supasil und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hydroxychloroquine (HCQ) has immunomodulatory and anti-inflammatory properties that may provide additional benefit in chronic proteinuric glomerulopathy (CGN). This study aimed to evaluate the short-term effects of adjunctive HCQ on proteinuria and inflammatory biomarkers in patients with stable CGN receiving optimized supportive therapy.
Methods
In this single-center, double-blind, placebo-controlled proof-of-concept randomized trial, 43 patients with CGN (urine protein-to-creatinine ratio of ≥0.5 g/g and estimated glomerular filtration rate [eGFR] of >20 mL/min/1.73 m2) were randomized to receive eGFR-adjusted HCQ (n = 21) or placebo (n = 22) for 4 months. The primary outcome was change in proteinuria; secondary outcomes included interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), eGFR, and safety.
Results
After 4 months, the median percentage change in proteinuria was −27.9% (IQR, −55.1 to −15.5) with HCQ versus +20.7% (IQR, −6.9 to +45.4) with placebo. In mixed-effects maximum-likelihood regression adjusted for systolic blood pressure, HCQ was associated with a greater reduction in proteinuria than placebo (β, −118.55; 95% CI, −208.07 to −29.03; p = 0.009). A ≥30% reduction in proteinuria occurred more frequently with HCQ than placebo (50.0% vs. 14.3%; p = 0.014). IL-6 and hsCRP were also reduced with HCQ. No significant between-group difference in eGFR or serious adverse events was observed.
Conclusion
Adjunctive HCQ was associated with a short-term reduction in proteinuria in patients with stable chronic proteinuric glomerulopathy receiving optimized supportive therapy. Exploratory reductions in IL-6 and hsCRP were also observed. These proof-of-concept findings support further evaluation of HCQ in larger, longer, biopsy-based, disease-specific randomized trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.
ORCID-Profile: Bancha Satirapoj
Zitieren
APA
Supasil, T., Thimachai, P., Supasyndh, O., & Satirapoj, B. (2026). Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Proof-of-Concept Randomized Controlled Trial (HCQ-CGN Trial). Glomerular Diseases, 6(1), 342-353. https://doi.org/10.1159/gdz/acyag005
Vancouver
Supasil T, Thimachai P, Supasyndh O, Satirapoj B. Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Proof-of-Concept Randomized Controlled Trial (HCQ-CGN Trial). Glomerular Diseases. 2026;6(1):342-353. doi:10.1159/gdz/acyag005
BibTeX
@article{Supasil2026,
author = {Supasil, Thitirat and Thimachai, Paramat and Supasyndh, Ouppatham and Satirapoj, Bancha},
title = {Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Proof-of-Concept Randomized Controlled Trial (HCQ-CGN Trial)},
journal = {Glomerular Diseases},
year = {2026},
volume = {6},
number = {1},
pages = {342--353},
doi = {10.1159/gdz/acyag005}
}
EUVIMED